The present specification includes a Breton tyrosine kinase (Btk) inhibitor, 1-((R) -3- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidine -1-yl) piperidin-1-yl) prop-2-en-1-one, including its crystalline form, solvates, and pharmaceutically acceptable salts, is described. Also, pharmaceutical compositions comprising Btk inhibitors for the treatment of autoimmune diseases or diseases, heteroimmune diseases or diseases, cancers including lymphoma, and inflammatory diseases or diseases, as well as alone or other therapies Also disclosed are methods of using a Btk inhibitor in combination with an agent. [Selection] Figure 1本明細書には、ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤、１－（（Ｒ）－３－（４－アミノ－３－（４－フェノキシフェニル）－１Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル）ピペリジン－１－イル）ｐｒｏｐ－２－ｅｎ－１－オン（その結晶形態、溶媒和物、及び薬学的に許容可能な塩を含む）が、記載される。また、自己免疫疾患又は疾病、異種免疫の疾患又は疾病、リンパ腫を含む癌、及び炎症性疾患又は疾病の処置のための、Ｂｔｋ阻害剤を含む医薬組成物、同様に、単独で又は他の治療剤と組み合わせてＢｔｋ阻害剤を使用する方法も、開示される。【選択図】図１
